The Journal of Neurosurgery Publishing Group is pleased to announce publication of two new studies on dabigatran etexilate (Pradaxa®) and intracranial hemorrhage: one in the Journal of Neurosurgery and the other in Neurosurgical Focus. Background Dabigatran is an oral anticoagulant (blood...
Bleeding rates linked to new use of Pradaxa (Dabigatran) are no higher than they are with new users of warfarin, says a new FDA Drug Safety communication report update (November 2, 2012). The FDA (Food and Drug Administration) carried out an evaluation on Pradaxa after receiving several...
Pradaxa (dabigatran etexilate), an anticoagulant, has been approved in capsule form for the prevention of blood clots and strokes in individuals with atrial fibrillation by the US Food and Drug Administration (FDA). People with atrial fibrillation - abnormal heart rhythm - are more susceptible...